Denmark-based Bavarian Nordic has reported positive topline data from a Phase III study of its virus-like particle (VLP)-based chikungunya virus vaccine CHIKV VLP (PXVX0317) in adults and adolescents.

The placebo-controlled, double-blind, randomised study enrolled a total of 3,254 participants aged 12 to 64 years.

They were randomised to receive either a single injection of the adjuvanted vaccine intramuscularly or placebo.

On day 22, chikungunya-neutralising antibodies were found in 98% of vaccinees in the active group who received the candidate.

The primary objective of the study was also met by reaching the threshold of antibodies, which were equal to or exceeded the levels, as agreed with authorities as a marker of seroprotection.

These antibodies were also found at two weeks after vaccination in 97% of the subjects proving a quick onset of protective immunity levels.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mild or moderate adverse events were reported in the adolescent and adult populations. However, the vaccine was well-tolerated in this group.

A similar Phase III study of the vaccine was carried out in adults ≥65 years of age, which demonstrated that the candidate induced neutralising antibodies in 87% of vaccinees on day 22.

Bavarian Nordic president and CEO Paul Chaplin said: “Our focus remains to finalise the studies and prepare for regulatory submissions next year.

“With a fast and durable response, our vaccine has the potential to be the best in class to prevent chikungunya infections in adolescents to elderly adults.”

“With international travel on the rise again, our CHIKV vaccine offers a significant opportunity to address this large unmet medical need.”

EMA granted PRIME designation to CHIKV VLP while FDA provided breakthrough therapy and fast track designations.

The company is also engaged in developing, manufacturing and marketing life-saving vaccines, including smallpox and mpox vaccines.